Labcorp Holdings (BMV:LH *) - Aandelenkoers, Nieuws & Analyse

LH * Overzicht aandelen

Labcorp Holdings Inc. biedt laboratoriumdiensten aan. Meer informatie

LH * fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	3/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 61.6% onder onze schatting van de reële waarde

De winst zal naar verwachting met 20.56% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Heeft een hoog schuldenniveau

Grote eenmalige posten die de financiële resultaten beïnvloeden

Labcorp Holdings Inc. Concurrenten

Quest Diagnostics

NYSE:DGX

US$18.1b

DaVita

NYSE:DVA

US$13.7b

Fresenius Medical Care

XTRA:FME

€12.3b

Sonic Healthcare

ASX:SHL

AU$13.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Labcorp Holdings
Historische aandelenkoersen
Huidige aandelenkoers	US$4,101.00
52 Week Hoogtepunt	US$4,370.00
52 Week Laag	US$3,524.01
Bèta	1.04
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	-27.59%
5 jaar verandering	27.56%
Verandering sinds IPO	46.22%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	LH *	MX Healthcare	MX Markt
7D	0%	1.5%	-0.9%
1Y	n/a	-16.2%	-4.1%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe LH * presteerde ten opzichte van de MX Healthcare.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe LH * presteerde ten opzichte van de MX markt.

Prijsvolatiliteit

Is LH *'s price volatile compared to industry and market?
LH * volatility
LH * Average Weekly Movement	n/a
Healthcare Industry Average Movement	5.9%
Market Average Movement	4.0%
10% most volatile stocks in MX Market	6.2%
10% least volatile stocks in MX Market	2.7%

Stabiele aandelenkoers: De aandelenkoers van LH * is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van LH * in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1995	61,975	Adam Schechter	www.labcorp.com

Labcorp Holdings Inc. levert laboratoriumdiensten. Het is actief via twee segmenten, Diagnostics Laboratories en Biopharma Laboratory Services. Het bedrijf biedt verschillende tests aan, zoals bloedchemische analyses, urineanalyses, bloedceltellingen, schildklier, PAP, hemoglobine A1C en vitamine D, prostaat-specifieke antigenen, seksueel overdraagbare aandoeningen, hepatitis C, microbiologische kweken en procedures, en alcohol- en ander middelenmisbruiktesten.

Labcorp Holdings Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Labcorp Holdings zich tot de beurswaarde?
LH * fundamentele statistieken
Marktkapitalisatie	Mex$412.61b
Inkomsten(TTM)	Mex$9.00b
Inkomsten(TTM)	Mex$262.70b

45.8x

Koers/Winstverhouding

1.6x

P/S-verhouding

Is LH * overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
LH * resultatenrekening (TTM)
Inkomsten	US$12.71b
Kosten van inkomsten	US$9.16b
Brutowinst	US$3.55b
Overige uitgaven	US$3.11b
Inkomsten	US$435.50m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	5.21
Brutomarge	27.92%
Nettowinstmarge	3.43%
Schuld/Eigen Vermogen Verhouding	83.2%

Hoe presteerde LH * op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

1.2%

Huidig dividendrendement

56%

Uitbetalingsratio

Betaalt LH * een betrouwbaar dividend?

Zie LH * dividendgeschiedenis en benchmarks

Wanneer moet je LH * kopen om een aanstaand dividend te ontvangen?
Labcorp Holdings dividenddata
Ex Dividend Datum	Nov 26 2024
Betaaldatum dividend	Dec 13 2024
Dagen tot Ex-dividend	2 days
Dagen tot dividendbetaaldatum	15 days

Betaalt LH * een betrouwbaar dividend?

Zie LH * dividendgeschiedenis en benchmarks

LH * Overzicht aandelen

Beloningen

Risicoanalyse

Labcorp Holdings Inc. Concurrenten

NYSE:DGX

US$18.1b

NYSE:DVA

US$13.7b

XTRA:FME

€12.3b

ASX:SHL

AU$13.8b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Labcorp Holdings Inc. Announces Chief Financial Officer Changes

Third quarter 2024 earnings released: EPS: US$2.02 (vs US$2.12 in 3Q 2023)

Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024

Labcorp Expands Sexually Transmitted Infection Test Offerings with Rapid Syphilis Test

Labcorp Holdings Inc. to Report Q3, 2024 Results on Oct 24, 2024

Labcorp Holdings Inc. (NYSE:LH) agreed to acquire 15% stake in SYNLAB AG (HMSE:SYAB) from Cinven Limited for €140 million.

Recent updates

Labcorp Holdings Inc. Announces Chief Financial Officer Changes

Third quarter 2024 earnings released: EPS: US$2.02 (vs US$2.12 in 3Q 2023)

Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024

Labcorp Expands Sexually Transmitted Infection Test Offerings with Rapid Syphilis Test

Labcorp Holdings Inc. to Report Q3, 2024 Results on Oct 24, 2024

Labcorp Holdings Inc. (NYSE:LH) agreed to acquire 15% stake in SYNLAB AG (HMSE:SYAB) from Cinven Limited for €140 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of an Asset Purchase Agreement to acquire Select Assets of BioReference Health, LLC for approximately $240 million.

Upcoming dividend of US$0.72 per share

CFO & Executive VP recently sold Mex$63m worth of stock

Insider recently sold Mex$54m worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q).

Second quarter 2024 earnings released: EPS: US$2.44 (vs US$1.75 in 2Q 2023)

Labcorp Holdings Inc. Receives FDA De Novo Marketing Authorization for Pgdx Elio™ Plasma Focus Dx

Labcorp Holdings Inc. Revises Financial Guidance for the Full Year 2024

Labcorp Declares Quarterly Cash Dividend, Payable on September 13, 2024

Labcorp Holdings Inc. to Report Q2, 2024 Results on Aug 01, 2024

Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials

Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio

Executive VP recently sold Mex$7.1m worth of stock

Dividend of US$0.72 announced

Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Labcorp Declares Quarterly Dividend, Payable on June 12, 2024

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Labcorp Launches Weight Loss Management Testing Solutions

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on March 13, 2024

Labcorp Announces the Launch and Availability of A New, FDA-Cleared Blood Test for Risk Assessment and Clinical Management of Severe Preeclampsia

Laboratory Corporation of America Holdings to Report Q4, 2023 Results on Feb 15, 2024

Labcorp Declares Quarterly Cash Dividend, Payable on March 13, 2024

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory business from Legacy Health System Insurance Company.

Geneoscopy, Inc. Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool Rna (Mt-Srna) Colorectal Cancer Screening Test

Labcorp Declares a Cash Dividend, Payable on December 12, 2023

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Outreach Laboratory Business of Baystate Health, Inc.

Laboratory Corporation of America Holdings to Report Q3, 2023 Results on Oct 26, 2023

Independent Director recently sold Mex$18m worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach Laboratory Business and Select Operating Assets from Tufts Medicine, Inc.

Upcoming dividend of US$0.72 per share at 1.3% yield

Second quarter 2023 earnings released: EPS: US$1.75 (vs US$3.89 in 2Q 2022)

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on September 8, 2023

Laboratory Corporation of America Holdings acquired Clinical Laboratory Division from Enzo Biochem, Inc. for approximately $115 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory services assets of Jefferson Health.

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach laboratory business from Legacy Health System Insurance Company.

Laboratory Corporation of America Holdings to Report Q2, 2023 Results on Jul 27, 2023

Laboratory Corporation of America Holdings Appoints Paul B. Rothman as a Member of the Board

Laboratory Corporation of America Holdings Launches Labcorp Plasma Focus

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire the outreach laboratory business and select assets of Providence Health & Services - Oregon.

Laboratory Corporation of America Holdings Appoints Mark S. Schroeder to Executive Vice President, President Diagnostics & Chief Operations Officer

First quarter 2023 earnings released: EPS: US$2.41 (vs US$5.28 in 1Q 2022)

Laboratory Corporation of America Holdings Provides Earnings Guidance for the Year 2023

Laboratory Corporation of America Holdings to Report Q4, 2022 Results on Feb 16, 2023

Labcorp Declares Cash Dividend on Common Stock, Payable on March 13, 2023

Labcorp Announces Executive Changes